SCHEMBL26614242

SCHEMBL26614242

O=C1c2cc([N+](=O)[O-])ccc2-n2c1nc1cc(Cl)cc(Cl)c1c2=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.67
▸ PIM1 P11309 1/20 0.67
▸ LIMK1 P53667 1/20 0.67
▸ TYRO3 Q06418 1/20 0.67
▸ MAPK14 Q16539 1/20 0.67
▸ CLK4 Q9HAZ1 1/20 0.67
▸ IDO1 P14902 11/20 0.65
▸ TDO2 P48775 7/20 0.65
▸ IDO2 Q6ZQW0 7/20 0.65
▸ APAF1 O14727 2/20 0.49
▸ CASP1 P29466 2/20 0.41
▸ CASP3 P42574 2/20 0.41
▸ CASP4 P49662 2/20 0.41
▸ CASP7 P55210 2/20 0.41
▸ CASP9 P55211 2/20 0.41
▸ CASP6 P55212 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ MITF O75030 1/20 0.41
▸ HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31382846 1.00 CHEK1 (0.67) CHEK1PIM1LIMK1TYRO3MAPK14
SCHEMBL31382863 0.89 CHEK1 (0.77) CHEK1PIM1LIMK1TYRO3MAPK14
SCHEMBL26614147 0.89 CHEK1 (0.77) CHEK1PIM1LIMK1TYRO3MAPK14
SCHEMBL31382864 0.83 IDO1 (0.73) CHEK1PIM1LIMK1TYRO3MAPK14
SCHEMBL26614143 0.83 IDO1 (0.73) CHEK1PIM1LIMK1TYRO3MAPK14
SCHEMBL26860827 0.82 TDO2 (0.62) CHEK1PIM1LIMK1TYRO3MAPK14
SCHEMBL26614108 0.81 CHEK1 (0.78) CHEK1PIM1LIMK1TYRO3MAPK14
SCHEMBL9221854 0.81 IDO1 (0.73) CHEK1PIM1LIMK1TYRO3MAPK14
SCHEMBL31382845 0.81 CHEK1 (0.78) CHEK1PIM1LIMK1TYRO3MAPK14
SCHEMBL26855996 0.81 APAF1 (0.50) CHEK1PIM1LIMK1TYRO3MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. 2025-05-29 — — US disclosed
EP-4514804-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF Viscient Bio, Inc. (US) 2025-03-05 — — EP disclosed
WO-2023211977-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. (US) 2023-11-02 — — WO disclosed
WO-2023211977-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. (US) 2023-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF IDO2, IDO1, TPSB2 CHEK1 3580/4885PIM1 3187/4885LIMK1 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback